Reduced-Intensity Allogeneic Hematopoietic Stem Cell Transplantation for Malignant Hematological Diseases

• Status: Completed
• Trial end date: 2008-03-01
• Target enrollment: 0
• Participant gender: All

Summary

To evaluate engraftment and toxicity of a reduced intensity preparative regimen for patients who receive a matched related or unrelated donor allogeneic stem cell transplant (ASCT) for malignant hematological diseases

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University of Oklahoma
• Treatments: Alemtuzumab; Busulfan; Fludarabine; Fludarabine phosphate

Criteria

Inclusion Criteria:

• Performance status 0-2

• Ejection fraction > 30%

• AST/ALT and bilirubin not > 4 times normal

• Creatinine clearance greater than 70 ml/min.

• FEV1 greater than 1.0 and diffusion capacity greater than 40%

• Age 18-75 years

• Patients must be at high risk for conventional regimen related toxicity

• Malignant hematologic disease that would otherwise be considered treatable with ASCT

Exclusion Criteria:

• Does not meet the above Inclusion criteria